Jade Biosciences, Inc. Common Stock (JBIO)
PHARMACEUTICAL PREPARATIONS
Jade Biosciences, Inc. Common Stock (JBIO) is listed on Nasdaq, where it has traded since April 29, 2025.
- Listed On
- Nasdaq
- Listed Since
- April 29, 2025
- Employees
- 55
- Market Cap
- $928M
About Jade Biosciences, Inc. Common Stock
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 149 institutions reported holding JBIO, with 72.9 million shares worth $1.6 billion in aggregate. The largest reported holder was FMR, with 9.1 million shares worth $202.8 million. Of the 5 largest holders listed below, 2 added shares and 3 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| FMR | 9,126,877 | $203M | Added 28.81% |
| Janus Henderson (Jupiter Topco) | 6,273,262 | $139M | Added 101.99% |
| Fairmount Funds Management | 4,553,494 | $101M | Unchanged |
| RA Capital Management | 3,671,083 | $82M | Unchanged |
| VR Adviser | 3,220,364 | $72M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is JBIO?
Jade Biosciences, Inc. Common Stock (JBIO) is listed on Nasdaq, where it has traded since April 29, 2025.
Who are the largest institutional holders of JBIO?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of JBIO were FMR, Janus Henderson (Jupiter Topco) and Fairmount Funds Management.
How many institutions own JBIO?
149 institutions reported a position in JBIO for the quarter ended June 30, 2026, worth $1.6 billion in total.
Did institutions buy or sell JBIO last quarter?
Of the 5 largest reported holders, 2 added shares and 3 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for JBIO.
Every reported institutional holder, plus insider and congressional trades in JBIO, on SentiSense.